Place of ECMO in the Management of Severe Refractory ARDS Associated With Covid-19

STUDY ECMO-COVID-19 : Place of ECMO in the Management of Severe Refractory ARDS Associated With Covid-19

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04343404

Acronym

ECMO-COVID-19

Enrollment

100

Registered

2020-04-13

Start date

2020-04-01

Completion date

2020-04-15

Last updated

2020-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Distress Syndrome

Keywords

Respiratory Distress Syndrome, ARDS, SARS-COV-2, Extracorporeal membrane oxygenation, ECMO, Veno-venous ECMO

Brief summary

Describe COVID-19 patients who are receiving ECMO-VV respiratory replacement and what happens to them.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Patient over the age of 18; * Diagnostic COVID-19 by RT-PCR; * Hospitalisation in resuscitation for the management of complications related to COVID-19 * Implanted ECMO-VV during hospitalisation; * Patient agreeing to participate in the study

Exclusion criteria

* Sujet under guardianship or trusteeship * Sujet under safeguard of justice

Design outcomes

Primary

Measure	Time frame
Retrospective description of COVID-19 patients receiving respiratory ECMO-VV supplementation and what happens to them	Files analysed retrospectily from March 1st, 2020 to April 15, 2020 will be examined

Countries

France

Outcome results